e-drug
[Top] [All Lists]

[e-drug] Prescrire International April Issue

E-DRUG: Prescrire International April Issue
-------------------------------------------

Go to english.prescrire.org for the contents of the latest issue of Prescrire 
International Prescrire is a non-profit, continuing education organisation that 
is completely independent of any ties to government or industry. Prescrire's 
managers and editorial staff sign a yearly statement certifying that they have 
no conflicts of interest. Prescrire's publications accept no advertising, 
grants or other outside support or any kind.

Prescrire International is totally funded by subscribers, with no support from 
the pharmaceutical industry or government. It is monthly and published 11 times 
a year. Health professionals in low-income countries (excluding drug companies) 
can benefit from a subscription to Prescrire International thanks to Solidarity 
Subscription Rates.

You will find full subscription details at english.prescrire.org

Contents of the April issue include:


EDITORIAL
==========
Screening: tell the truth
Informing patients does not necessarily imply lower participation
FREE


NEW PRODUCTS
==============
Boceprevir
In triple-drug combination: virological advantage in chronic hepatitis C

Telaprevir
After boceprevir, if necessary

INN common stem: -previr


ADVERSE EFFECTS
================
Bupropion: congenital heart defects
Yet another reason to avoid bupropion

Opioids and hypogonadism
Patients should be informed

Publicly accessible pharmacovigilance databases
Already available in 4 countries

Fingolimod: cardiovascular deaths
Pharmacovigilance confirms adverse signals noticed prior to market release


REVIEWS
========
HIV exposure through contact with body fluids

Urgently assess the risk of infection and treat for 28 days if necessary

Assessing the risk of HIV infection after an isolated exposure incident

The French procedure for emergency management of HIV exposure


OUTLOOK
=========
New drugs and indications in 2011. France is better focused on patients' 
interests after the Mediator° scandal, but stagnation elsewhere
FREE

Drugs best avoided yet still on the market in early 2012
FREE
French drug policy: a few timid steps taken in 2011
FREE

In the wake of the Mediator° scandal: some progress in France, but apathy at 
the European level
FREE

Fingolimod (Gilenya°): EMA's lack of transparency spells danger for patients
FREE

MASTHEAD
FREE


Bruno TOUSSAINT
Editorial Director
Prescrire
75558 PARIS CEDEX 11
FRANCE


<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] Prescrire International April Issue, international <=